JP2021525530A5 - - Google Patents
Info
- Publication number
- JP2021525530A5 JP2021525530A5 JP2020567078A JP2020567078A JP2021525530A5 JP 2021525530 A5 JP2021525530 A5 JP 2021525530A5 JP 2020567078 A JP2020567078 A JP 2020567078A JP 2020567078 A JP2020567078 A JP 2020567078A JP 2021525530 A5 JP2021525530 A5 JP 2021525530A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- ggggs
- antigen
- recognition domain
- fusion protein
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679597P | 2018-06-01 | 2018-06-01 | |
| US62/679,597 | 2018-06-01 | ||
| PCT/US2019/034981 WO2019232425A1 (en) | 2018-06-01 | 2019-05-31 | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525530A JP2021525530A (ja) | 2021-09-27 |
| JP2021525530A5 true JP2021525530A5 (https=) | 2022-06-30 |
| JPWO2019232425A5 JPWO2019232425A5 (https=) | 2022-06-30 |
Family
ID=68696762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567078A Pending JP2021525530A (ja) | 2018-06-01 | 2019-05-31 | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20200054675A1 (https=) |
| EP (1) | EP3802578A4 (https=) |
| JP (1) | JP2021525530A (https=) |
| CN (1) | CN112533942A (https=) |
| WO (1) | WO2019232425A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ750256A (en) | 2016-08-03 | 2026-02-27 | Dipersio John F | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| SG11202011383VA (en) * | 2018-05-31 | 2020-12-30 | Univ Washington | Chimeric antigen receptor t cells (car-t) for the treatment of cancer |
| JP2022516389A (ja) * | 2018-05-31 | 2022-02-28 | ワシントン・ユニバーシティ | 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞 |
| JP2021525530A (ja) | 2018-06-01 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| WO2021041806A1 (en) | 2019-08-30 | 2021-03-04 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
| AU2020405049A1 (en) * | 2019-12-17 | 2022-06-23 | The General Hospital Corporation | Engineered immune cells with reduced toxicity and uses thereof |
| EP3845646A1 (en) * | 2019-12-30 | 2021-07-07 | Secarna Pharmaceuticals GmbH & Co. KG | Modified antisense oligonucleotide for inhibition of foxp3 expression |
| JP2023514407A (ja) * | 2020-02-24 | 2023-04-05 | アロジーン セラピューティクス，インコーポレイテッド | 増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞 |
| JP2023521519A (ja) * | 2020-04-06 | 2023-05-24 | セレディット エルエルシー | キメラ抗原受容体を発現し低減した炎症性サイトカインシグナル伝達を有する遺伝子改変された免疫細胞 |
| CN111548420B (zh) * | 2020-05-14 | 2021-10-15 | 深圳普瑞金生物药业有限公司 | 一种抗间皮素嵌合抗原受体、表达基因、表达载体、t细胞及其用途 |
| WO2022098756A1 (en) * | 2020-11-03 | 2022-05-12 | WUGEN, Inc. | Chimeric antigen receptor cell therapy |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| IL304904A (en) * | 2021-02-01 | 2023-10-01 | St Phi Therapeutics Co Ltd | Target protein degradation system and its use |
| CN112876535B (zh) * | 2021-02-08 | 2023-06-30 | 浙江华缔药业集团医药开发有限公司 | 生物活性多肽及其应用 |
| AU2022311936A1 (en) * | 2021-07-16 | 2024-02-29 | George GENTSCH | Gene editing to improve joint function |
| CN118056012B (zh) * | 2021-08-24 | 2025-05-30 | 赛斯尔擎生物技术（上海）有限公司 | 一种修饰细胞的方法 |
| CN114410686B (zh) * | 2021-12-24 | 2023-10-03 | 武汉大学 | 一种工程化外泌体原位纳米疫苗及其制备方法和应用 |
| EP4504221A4 (en) * | 2022-03-22 | 2026-02-25 | Celyntra Therapeutics Sa | Compositions and methods for generating cells with reduced immunogenicity |
| US20250302918A1 (en) * | 2022-05-20 | 2025-10-02 | President And Fellows Of Harvard College | Methods and compositions relating to treatment of cns diseases |
| CN116102662A (zh) * | 2022-10-10 | 2023-05-12 | 武汉波睿达生物科技有限公司 | 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用 |
| AU2023362748A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| AU2023362749A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| JP2025535441A (ja) * | 2022-10-20 | 2025-10-24 | マイクロ クリスパー プライベート リミテッド | 免疫療法におけるサイトカイン放出症候群の軽減 |
| CN116240173B (zh) * | 2023-02-02 | 2024-09-27 | 西安电子科技大学 | 一种冷热肿瘤调控型car-单核/巨噬细胞及其制备方法和应用 |
| CN116199781B (zh) * | 2023-02-22 | 2025-07-18 | 成都优赛诺生物科技有限公司 | 一种靶向cd22的单域抗体、嵌合抗原受体及其应用 |
| CN116754774B (zh) * | 2023-05-12 | 2026-03-06 | 浙江大学医学院附属第一医院 | 一种细胞因子组合物及应用 |
| WO2025077790A1 (en) * | 2023-10-11 | 2025-04-17 | Chengdu Ucello Biotechnology Co., Limited | Engineered immune cells and uses thereof |
| CN117186202B (zh) * | 2023-11-08 | 2024-02-02 | 北京大学第三医院（北京大学第三临床医学院） | 一种新细胞因子csbf及其在干眼治疗中的应用 |
| CN117866110B (zh) * | 2023-12-27 | 2024-06-11 | 广东唯泰生物科技有限公司 | 一种靶向flt-3的第四代嵌合抗原受体及其应用 |
| CN119345372A (zh) * | 2024-10-28 | 2025-01-24 | 北京大学人民医院 | Cd132在治疗aml中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4461308T (lt) | 2012-07-13 | 2025-06-10 | The Trustees Of The University Of Pennsylvania | Car priešnavikinio aktyvumo toksiškumo valdymas |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| CN113354744A (zh) | 2013-12-20 | 2021-09-07 | 弗雷德哈钦森癌症研究中心 | 带标签的嵌合效应分子及其受体 |
| JP6556156B2 (ja) * | 2014-02-27 | 2019-08-07 | ユーシーエル ビジネス ピーエルシー | Ａｐｒｉｌバリアント |
| CN113713091A (zh) * | 2015-02-06 | 2021-11-30 | 新加坡国立大学 | 工程免疫细胞及其用途和生产方法 |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11377637B2 (en) * | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| NZ750256A (en) | 2016-08-03 | 2026-02-27 | Dipersio John F | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| EP3519443A4 (en) * | 2016-09-30 | 2020-06-10 | Baylor College of Medicine | CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE |
| CN106636090B (zh) * | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2018132513A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | T cells experessing a chimeric antigen receptor |
| EP3691663A4 (en) * | 2017-10-02 | 2021-08-18 | Humanigen, Inc. | METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST |
| KR20200075851A (ko) | 2017-10-19 | 2020-06-26 | 셀렉티스 | 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합 |
| WO2019099993A1 (en) | 2017-11-17 | 2019-05-23 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for alleviating cytokine release syndrome |
| JP2021525530A (ja) | 2018-06-01 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
-
2019
- 2019-05-31 JP JP2020567078A patent/JP2021525530A/ja active Pending
- 2019-05-31 WO PCT/US2019/034981 patent/WO2019232425A1/en not_active Ceased
- 2019-05-31 CN CN201980044894.5A patent/CN112533942A/zh active Pending
- 2019-05-31 US US16/428,362 patent/US20200054675A1/en not_active Abandoned
- 2019-05-31 EP EP19810633.8A patent/EP3802578A4/en not_active Withdrawn
-
2022
- 2022-05-17 US US17/746,645 patent/US12304941B2/en active Active
-
2025
- 2025-03-19 US US19/084,433 patent/US20260022156A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525530A5 (https=) | ||
| JPWO2019232425A5 (https=) | ||
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2024083331A5 (https=) | ||
| JP2025109759A5 (https=) | ||
| IL275743A (en) | New bispecific format suitable for use in high-through-put screening | |
| JP2021525518A5 (https=) | ||
| JP2018172439A5 (https=) | ||
| JP2021525524A5 (https=) | ||
| US20170073415A1 (en) | Novel multispecific molecules and novel treatment methods based on such multispecific molecules | |
| JP2017504578A5 (https=) | ||
| RU2016138347A (ru) | Трифункциональная антигенсвязывающая молекула | |
| WO2002002781A1 (en) | Heterodimeric fusion proteins | |
| JP2017522891A5 (https=) | ||
| JP2016536322A5 (https=) | ||
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| JP2020522267A (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP2021515798A5 (https=) | ||
| JP2020516603A5 (https=) | ||
| JP2022009816A5 (https=) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| TWI690539B (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| JPWO2021184673A5 (https=) | ||
| JP7839238B2 (ja) | ｍＲＮＡディスプレイ抗体ライブラリー及び方法 |